
July 23 (Reuters) - Avidity Biosciences Inc RNA.O:
AVIDITY BIOSCIENCES RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DELPACIBART ZOTADIRSEN (DEL-ZOTA) FOR THE TREATMENT OF DMD IN PEOPLE WITH MUTATIONS AMENABLE TO EXON 44 SKIPPING
AVIDITY BIOSCIENCES INC - ON TRACK FOR BLA SUBMISSION FOR DEL-ZOTA BY YEAR-END 2025
AVIDITY BIOSCIENCES INC - DEL-ZOTA SHOWS SIGNIFICANT INCREASES IN EXON SKIPPING AND DYSTROPHIN